Nexalin Technology, Inc. (NXL) vs Trinity Biotech PLC (TRIB)
Nexalin Technology, Inc. and Trinity Biotech PLC are both Medical Devices companies. Trinity Biotech PLC is the larger, with a market value of $4.5M against $3.6M — 1.2× the size. Nexalin Technology, Inc. grew revenue faster over the last twelve months: 24.3% against −13.5%. Trinity Biotech PLC has the higher net margin (−70.1% vs −4,138.5%) and the higher return on invested capital (−12.6% vs −1,108.8%). Across the 17 metrics below, Trinity Biotech PLC leads on 10 and Nexalin Technology, Inc. on 7.
Valuation
Profitability
| Metric | NXL | TRIB | Medical Devices median |
|---|---|---|---|
| Gross margin | 86.14% | 39.99% | 56.01% |
| Operating margin | (4,201.66%) | (25.43%) | (15.03%) |
| Net margin | (4,138.49%) | (70.07%) | (20.40%) |
| Free cash flow margin | (2,917.96%) | (9.10%) | (7.24%) |
| Return on equity | (240.25%) | 55.26% | (15.32%) |
| Return on assets | (187.89%) | (32.70%) | (19.72%) |
| Return on invested capital | (1,108.82%) | (12.61%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack